FDA Historical Calendar

TickerCurrent price52 hi52 loProductIndicationPDUFA dateDecisionNotes
PTX5.4512.885.06TREXIMETAdolescent migraine patients5/14/2015Approved Approved May 15 2015
THRX16.7729.3210.58BREO ELLIPTAAsthma4/30/2015Approved April 30 2015. Approved April 30 2015
MDCO33.5033.7719.92RAPLIXAHemostasis4/30/2015ApprovedApproved April 30 2015
MDCO33.5033.7719.92IONSYSAcute postoperative painApproved5/2/2015
KYTH74.6376.3129.86ATX-101 Reduction of Localized Subcutaneous Fat in the Submental Area5/13/2015ApprovedApproved April 29 2015
LLY88.7090.1860.14CYRAMZASecond-Line Treatment of Metastatic Colorectal CancerApprovedApproved April 24 2015
MNTA22.7925.569.38Generic CopaxoneMultiple sclerosisApprovedFiled 2007. Approved mid April 16 2015
AMGN159.42173.60114.93CorlanorChronic Heart Failure5/27/2015ApprovedApproved April 15 2015
EBS34.0034.4919.31Anthrax Immune Globulin Intravenous (Human) [AIGIV] AnthraxApprovedApproved March 25 2015
VRTX127.46137.5084.41Vacaftor Children ages 2 to 5 with cystic fibrosis who have the G551D or one of the eight additional gating mutations3/17/2015ApprovedApproved March 17 2015
BMY69.8569.9147.54OpdivoAdvanced Squamous Non-Small Cell Lung Cancer6/22/2015ApprovedApproved March 4 2015
PCRX67.77121.9565.00EXPARELSingle-dose injection femoral nerve block for total knee arthroplasty surgery3/5/2015CRLPDUFA CRL March 2 2015.
SNY53.1557.4243.57ToujeoType 1 and type 2 diabetesApprovedApproved Feb 26 2015
ESALY52.1580.4135.79Lenvatinib mesylate (lenvatinib)Differentiated thyroid cancer (DTC) 4/14/2015ApprovedApproved Feb 13 2015
PCYC261.25261.6882.51IMBRUVICAWaldenström’s Macroglobulinemia4/17/2015ApprovedApproved Jan 29, 2015
ZGNX17.6717.868.56 Abuse deterrent formulations of Zohydro ERModerate to severe pain1/30/2015ApprovedApproved January 30 2015
RMTI17.8218.308.10Soluble Ferric PyrophosphateIron deficiency1/24/2015ApprovedApproved Jan 26 2015
NPSPNatparaHypoparathyroidism1/24/2015ApprovedApproved Jan 23 2015
IPXL48.4952.1022.12IPX066Parkinson's Approved Jan 8 2015
VRTX127.46137.5084.41KALYDECOCystic fibrosis (CF) ages 6 and older who have the R117H mutation12/30/2014ApprovedApproved Dec 28 2014
ADMS28.4829.7413.60NamzaricModerate to severe dementia of the Alzheimer's type.ApprovedApproved Dec 24 2014
BCRX16.2816.437.85Peramivir INFLUENZA ACUTE 12/23/2014ApprovedApproved Dec 22 2014
ENTA48.0352.5830.13VIEKIRA PAKHCV - genotype 112/21/2014ApprovedApproved December 19 2014
ABBV69.9070.7651.37VIEKIRA PAKHCV - genotype 112/21/2014ApprovedApproved December 19 2014
CBST101.94101.9958.50Ceftolozane/ tazobactam ZERBAXAComplicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI)12/21/2014ApprovedApproved Dec 21 2014- priority review
POZN10.7912.695.96PA32540 and PA8140Cardiovascular patients at risk for developing aspirin-associated gastric ulcers12/30/2014CRLCRL Apr 25 2014. Further CRL issued Dec 17 2014 - due to deficiencies with facility. Intends to schedule a Type A meeting with FDA to address issues
INCY117.03117.4243.86Jakafi Polycythemia Vera5/12/2014ApprovedApproved December 4 2014
AVNR16.9617.053.02AVP-825Acute migraine11/26/2014CRLCRL November 26 2014 - likely to resubmit 1H 2015
AEZS0.241.540.23Macimorelin AcetateAdult Growth Deficiency 11/5/2014CRL New trials required
PGNX8.049.274.26Subcutaneous RELISTORChronic pain9/29/2014Approved
SLXP172.81172.9886.00Subcutaneous RELISTORChronic pain9/29/2014Approved
ALIM4.846.543.98IluvienDiabetic macular edema9/26/2014Approved Sept 26 2014
PSDV4.494.943.23IluvienDiabetic macular edema9/26/2014Approved Sept 26 2014
AUXL36.4737.9217.10AvanafilErectile dysfunction9/20/2014ApprovedApproved 9/18/2014 - sNDA to change label allowing use 15 minutes before sexual activity.
VVUS2.295.132.05AvanafilErectile dysfunction9/20/2014ApprovedApproved 9/18/2014 - sNDA to change label allowing use 15 minutes before sexual activity.
NKTR12.0017.539.51NaloxegolOpioid-induced constipation (OIC)9/16/2014ApprovedApproved Sept 16 2014
SLXP172.81172.9886.00Budesonide foamModerate ulcerative proctitis or proctosigmoiditis 9/15/2014Tentative approvalTentative approval granted September 15 2014 pending patent issues
HALO24.1124.707.51HYQVIASubcutaneous treatment for patients with primary immunodeficiency (PI)ApprovedApproved Sept 12 2014
OREX4.829.373.11ContraveObesity9/11/2014ApprovedApproved September 11 2014
MDVN108.47141.5869.11XTANDICancer - mCRPC who have not received chemotherapy9/17/2014ApprovedApproved Sept 10 2014
KERX9.9418.488.84ZerenexHyperphosphatemia9/7/2014ApprovedApproved Sept 5 2014
LGND104.73104.9841.99PromactaAplastic AnemiaApproved Approved August 27 2014
MDCO33.5033.7719.92OritavancinABSSSI8/6/2014ApprovedApproved under priority review
PCYC261.25261.6882.51Ibrutinib Deletion 17pApprovedApproved July 29 2014
PCYC261.25261.6882.51Ibrutinib Cancer - Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma (CLL/SLL)ApprovedApproved July 29 2014
ACRX4.3711.382.96ZalvisoPost-operative pain following open abdominal surgery and hip or knee replacement surgery7/27/2014CRLCRL Jul 26 2014
EGRX90.3292.1210.06RyanodexMalignant hyperthermia7/22/2014Approved
SLXP172.81172.9886.00RUCONESTHereditary angioedema (HAE)7/16/2014Approved Partnered with Dutch company Pharming
ANAC126.32135.7515.11TavaboroleOnychomycosis7/29/2014ApprovedApproved July 8 2014
SPPI7.278.505.45BelinostatCancer - Peripheral T-Cell Lymphoma8/9/2014ApprovedApproved two months early under accelerated approval program.
EGRX90.3292.1210.06EP-3101 (bendamustine RTD) Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma7/6/2014Approved - tentativeTentative approval (July 2 2014) will convert to a final approval subject to patent litigation with Teva Pharmaceutical
FLML22.6122.909.30VAZCULEP (phenylephrine hydrochloride)Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia8/6/2014ApprovedApproved June 30 2014. PDUFA of August 6 was for a resubmission following CRL
NPSP0.00#N/A#N/AGATTEXShort Bowel Syndrome 7/28/2014ApprovedsNDA - seeking additions to label
MNKD5.5610.183.46AFREZZA Type 1/2 diabetes7/15/2014ApprovedApproved June 27 2014
CBST101.94101.9958.50Tedizolid phosphateAcute bacterial skin and skin structure infections (ABSSSI)6/22/2014Approved Approved June 20 2014
NAVB1.752.020.97LymphoseekHead and Neck Cancer6/16/2014ApprovedApproved Jun 13 2014
BDSI8.8818.487.17BEMA Buprenorphine/Naloxone (BNX) - BUNAVAILOpioid dependence6/7/2014ApprovedApproved June 7 2014
OMER18.7427.6411.18OmidriaCataract surgery6/1/2014Approved Approved June 2 2014
TRLPF0.500.650.29Loading...PDUFA5/28/2014PDUFA date February 28 2014, extended to May 28 2014, for bioadhesive intranasal gel testosterone product (CompleoTRT)
QRXPY0.030.410.03MOXDUOModerate to severe acute pain5/25/2014CRL
DRTX0.00#N/A#N/ADalbavancinAcute bacterial skin and skin structure infections (ABSSSI)5/26/2014ApprovedApproved May 23 2014
FLML22.6122.909.30??????4/28/2014CRLCRL April 28 2014
MDCO33.5033.7719.92CangrelorReduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI).4/30/2014CRLCRL April 30 2014
POZN10.7912.695.96PA32540 and PA8140Cardiovascular patients at risk for developing aspirin-associated gastric ulcers4/25/2014CRLCRL Apr 25 2014 - manufacturing deficiencies
TSX:PLBImpavidoTropical disease leishmaniasis3/19/2014ApprovedApproved Mar 19
BMY69.8569.9147.54Eliquis To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery3/15/2014ApprovedApproved March 14 2014
PFE34.9335.5327.51EliquisTo Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery3/15/2014ApprovedApproved March 14 2014
ENDP85.2596.5857.14AVEED (testosterone undecanoate) intramuscular injectionMen diagnosed with hypogonadism3/28/2014ApprovedApproved March 6 2014
AZN67.8776.2463.22MetreleptinLipodystrophy2/27/2014ApprovedApproved Feb 25 2014
BMY69.8569.9147.54MetreleptinLipodystrophy2/27/2014ApprovedApproved Feb 25 2014
CHTPNORTHERA Neurogenic Orthostatic HypotensionApprovedApprovedApproved one day late due to snow. Acquired by Lundbeck
BMRN147.25147.3555.36Vimizim (GALNS)(MPS IVA) Morquio A Syndrome2/28/2014Approved Early approval. Was under priority review
DRRX2.513.420.68PosidurPost-operative pain relief 2/12/2014CRL
PCYC261.25261.6882.51Ibrutinib Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy2/28/2014ApprovedApproved Feb 12 2014
VNDA12.4515.518.34HETLIOZ (tasimelteon)Non-24-Hour Sleep-Wake Disorder1/31/2014Approved
VRX237.12246.01106.00Retin-A Micro (tretinoin) Gel microsphere 0.08% Acne vulgarisApprovedsNDA
AMAG74.1274.5217.79FerahemeIron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) to all adult patients with IDA who have failed or could not tolerate oral iron treatment1/21/2014CRLOriginal PDUFA date delayed
AZN67.8776.2463.22FARXIGA (dapagliflozin) tablets Adult patients with type 2 diabetesApproved
BMY69.8569.9147.54FARXIGA (dapagliflozin) tabletsAdult patients with type 2 diabetesApproved
GSK43.3053.8241.19Mekinist (trametinib) and Tafinlar (dabrafenib)Unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutationsApprovedAccelerated approval based on Phase 2 trial. Approval coningent on Phase 3 trial outcome
MRK57.9463.6252.49ISENTRESS for oral suspensionHIV-1 infected infants and childrenApproved
AZN67.8776.2463.22Forxiga (dapagliflozin)Type 2 diabetes1/11/2014ApprovedApproved three days prior to PDUFA
BMY69.8569.9147.54Forxiga (dapagliflozin)Type 2 diabetes1/11/2014ApprovedApproved three days prior to PDUFA
SNY53.1557.4243.57LemtradaRelapsing forms of multiple sclerosis.CRLCRL 29/12/13
UTHR173.94190.2986.04Oral treprostinilPulmonary arterial hypertension (PAH)2/16/2014ApprovedApproved Dec 20 2013. Early approval following previous extension
THRX16.7729.3210.58UMEC/VI (62.5/25mcg and 125/25mcg doses) ANORO ELLIPTAChronic Obstructive Pulmonary Disease (COPD)12/18/2013ApprovedApproved Dec 18 2013
JNJ99.24109.4995.10Canagliflozin and immediate-release metforminAdults with type 2 diabetesCRL
GILD117.38123.3784.75Sovaldi (Sofosbuvir)HCV6/12/2013Approved
AUXL36.4737.9217.10XIAFLEXPeyronie’s6/12/2013ApprovedApproved Dec 6 2013
PCYC261.25261.6882.51Ibrutinib versus temsirolimus - RAY (MCL3001)Cancer - relapsed or refractory MCL mantle cell lymphoma2/28/2013Approved Approved Nov 13 2013, 3 months early. Was under priority review
ZGNX17.6717.868.56Zohydro ERModerate to severe painApprovedApproved Oct 25 2013. Decision was delayed by several months
AGN320.80321.92201.91JUVÉDERM VOLUMA XCAge-related volume loss in the cheek area in adults over the age of 21ApprovedApproved Oct 23 2013
ALIOF149.45156.06103.65Macitentan (Opsumit)Pulmonary arterial hypertension10/18/2013ApprovedApproved Oct 18 2013
ALIM4.846.543.98IluvienDiabetic macular edema10/17/2013CRLCRL Nov 2011. Second CRL Oct 17 2013. Adcom meeting Jan 27 2014
PSDV4.494.943.23IluvienDiabetic macular edema10/17/2013CRLCRL Nov 2011. Second CRL Oct 17 2013. Adcom meeting Jan 27 2014
ATRS2.293.041.82OTREXUPRheumatoid arthritis (RA)10/14/2013ApprovedApproved Oct 14 2013
DCTH0.862.780.80CHEMOSAT systemCancer - unresectable metastatic ocular melanoma in the liver9/13/2013CRL CRL Sept 13 2013
CELG122.75129.0682.90ABRAXANEMetastatic pancreatic cancer9/21/2013ApprovedApproved Sep 6 2013
QRXPY0.030.410.03MOXDUOModerate to severe acute pain8/26/2013CRLCRL Aug 2013. Expects to resubmit 4Q 2013. Expects Adcom meeting
SUPN18.7119.557.31Trokendi XR SPN-538EpilepsyApprovedApproved Aug 19 2013
JNJ99.24109.4995.10SIMPONI ARIARheumatoid ArthritisApprovedApproved Jul 18 2013
MRK57.9463.6252.49Suvorexant tabletsInsomniaCRLAdcom May 22 2013. 13-3 positive vote. CRL received Jul 1 2013
GSK43.3053.8241.19Dolutegravir - ViiV HealthcareHIV8/17/2013ApprovedPDUFA Aug 12 under priority review.
JNJ99.24109.4995.10XARELTO (rivaroxaban)Stent Thrombosis in Patients with Acute Coronary SyndromeCRLCRL issued Jun 28 2013
THRX16.7729.3210.58VIBATIV (telavancin hydrochloride) for injectionHospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)ApprovedApproved Jun 21 2013
AMGN159.42173.60114.93XGEVACancer - Giant Cell Tumor Of BoneApprovedApproved 6/13/13
AVEO1.593.500.61TivozanibCancer - advanced renal cell carcinoma7/28/2013CRLNegative 1-13 vote at Adcom meeting May 2 2013.Early CRL Jun 10 2013
CELG122.75129.0682.90REVLIMIDCancer - relapsed/refractory mantle cell lymphomaApproved Approved Jun 5 2013 under priority review
FLML22.6122.909.30Bloxiverz (neostigmine methylsulfate)Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery5/31/2013ApprovedApproved Jun 3 2013
DEPO30.8231.189.85SEFELSAHot flashes5/31/2013CRLCRL May 31 2013
ENDP85.2596.5857.14AVEED (testosterone undecanoate) intramuscular injectionMen diagnosed with hypogonadismCRLCRL issued May 30 2013. Expects to respond 3Q 2013
GSK43.3053.8241.19DabrafenibCancer - melanoma6/3/2013Approved Approved May 29 2013
GSK43.3053.8241.19TrametinibCancer - melanoma6/3/2013ApprovedApproved May 29 2013
VRX237.12246.01106.00EfinaconazoleOnychomycosis5/24/2013CRLCRL May 28 2013
JNJ99.24109.4995.10SIMPONI (golimumab) ulcerative colitis (UC)ApprovedApproved May 16
THRX16.7729.3210.58BREO ELLIPTAChronic Obstructive Pulmonary Disease (COPD)5/12/2013ApprovedApproved May 10 2013
GSK43.3053.8241.19BREO ELLIPTAChronic Obstructive Pulmonary Disease (COPD)5/12/2013ApprovedApproved May 10 2013
BMY69.8569.9147.54SUSTIVA® (efavirenz)HIV-1ApprovedsNDA approved May 3 2013
MRK57.9463.6252.49LIPTRUZET (ezetimibe and atorvastatin)LDL CholesterolApprovedApproved May 3 2013
SHPG256.88264.98156.25Vyvanse® (lisdexamfetamine dimesylate) Children and Adolescents with ADHD5/1/2013ApprovedApproved May 1 2013
TTNP0.720.990.44ProbuphineOpioid dependence4/30/2013CRLCRL issued midnight Apr 30
RPTP14.8016.287.85DR CysteamineCystinosis4/30/2013ApprovedApproved Apr 30, 2013.
GILD117.38123.3784.75ElvitegravirHIV4/27/2013CRLCRL Apr 29 2013
GILD117.38123.3784.75CobicistatHIV4/28/2013CRLCRL Apr 29 2013
SCMP18.3822.005.80Amitiza/ LubiprostoneOpioid-induced bowel dysfunction4/24/2013ApprovedApproved Apr 23 2013
NVS105.61105.8284.17Simbrinza(TM) SuspensionGlaucomaApprovedApproved Apr 19 2013
JNJ99.24109.4995.10InvokanaType 2 diabetes3/31/2013ApprovedApproved Mar 29 2013
APPA32.78APF530Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV)3/27/2013CRLCRL Mar 28 2013. Changed ticker to HRTX
UTHR173.94190.2986.04Treprostinil diolamine extended release tablets (oral treprostinil)Pulmonary arterial hypertension3/31/2013CRLCRL Mar 25, 6 days early
NAVB1.752.020.97LymphoseekLymphatic-tissue tracing agent4/30/2013Approved Approved Mar 13 2013. 7 weeks early.
JNJ99.24109.4995.10XARELTOReduction of the risk of cardiovascular events in patients with acute coronary syndrome (ACS)3/5/2013CRLCRL March 5 2013
ONXXStivargaMetastatic and/or unresectable gastrointestinal stromal tumors (GIST)2/25/2013ApprovedApproved Feb 25 2013. Acquired by Amgen.
DVAX28.9829.8313.10HEPLISAVHepatitis B2/24/2013CRLCRL Feb 25 2013. Hopes to meet with FDA by mid April to discuss CRL
IMGN16.8417.245.34KadcylaCancer - 2nd-line HER2+ Metastatic Breast Cancer2/26/2013ApprovedApproved Feb 22 2013 - under priority review
NVS105.61105.8284.17Zortress (everolimus)Prevent organ rejection in adult liver transplant patientsApprovedApproved Feb 15 2013
CELG122.75129.0682.90PomalystCancer - Multiple Myeloma2/10/2013ApprovedApproved Feb 8 2013
HEB0.200.400.17Ampligen CFS2/4/2013CRLCRL Feb 4 2012. Resubmission. More trials required. Intends to appeal
HPTX45.9946.9620.23RavictiUrea cycle disorders1/22/2013ApprovedApproved Feb 1 2013. FDA had advised company of delay
FURX0.00#N/A#N/AAlogliptinDiabetes - Type 21/27/2013Approved NDA resubmitted July 27 2012, following CRL. Approved Jan 25 2013
IPXL48.4952.1022.12IPX066Parkinson's 1/21/2013CRLCRL January 21 2013
PATHZecuity Migraine1/17/2013ApprovedApproved Jan 17 2013. Acquired by TEVA.
SNTSBudesonideUCERIS (Budesonide)Ulcerative colitis disease1/16/2013ApprovedApproved Jan 14 2013, two days early. Acquired by Salix.
AEGR18.6636.6816.68LomitapideHomozygous familial hypercholesterolemia (HoFH)1/6/2013ApprovedEarly approval Dec 24 2012
ALXA1.165.270.80Staccato loxapine (ADASUVE). Schizophrenia12/21/2012Approved
NPSP0.00#N/A#N/AGattexShort bowel syndrome or SBS12/30/2012ApprovedPDUFA date was Dec 30 2012. Early approval on Dec 21
ARIA8.449.894.90Oral ponatinibCancer - chronic myeloid leukemia, acute lymphoblastic leukemia3/27/2013ApprovedPDUFA March 27 2013. Early approval Dec 14 2012 under priority review
EXEL3.894.551.26CabozantinibCancer - Medullary thyroid 11/29/2012ApprovedApproved Nov 29 2012 under priority review
LGND104.73104.9841.99Promacta/RevoladeThrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C11/30/2012ApprovedApproved Nov 19 2012 under priority review, 11 days prior to PDUFA date
CRTXCRTX 080Hyponatremia10/29/2012CRLAdditional clinical and non-clinical information required. Acquired by Chiesi Farmaceutici S.p.A
SUPN18.7119.557.31OxtellarEpilepsy10/22/2012Approved
NAVB1.752.020.97LymphoseekLymphatic-tissue tracing agent9/10/2012CRL3rd party manufacturing deficiencies cited
MDVN108.47141.5869.11MDV3100Cancer - prostate 2nd line8/31/2012Approved Early approval decision by 3mths approx. Was under priority review
TLON0.161.830.13Marqibo2nd line adult Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)8/12/2012Approved Approved 8/9/2012
HALO24.1124.707.51HyQPrimary immunodeficiency diseaseCRL
PGNX8.049.274.26Subcutaneous RELISTORchronic pain7/27/2012CRLPrice shown is for PGNX. Partnered with SLXP
AMRN2.473.330.78Vascepa Elevated triglyceride levels7/26/2012Approved
HZNP35.6736.307.85LODOTRA (RAYOS)Rheumetoid Arthritis7/26/2012Approved
ONXXCarfilzomibMultiple myeloma7/20/2012ApprovedAcquired by Amgen.
VVUS2.295.132.05QnexaObesity7/18/2012Approved
ARNA4.486.283.26LorcaserinObesity6/27/2012Approved
QRX0.030.100.01MOXDUOModerate to severe acute pain6/26/2012CRL
RGEN41.3142.4818.23RG1068Detection of pancreatic duct abnormalities6/22/2012CRL
XNPT7.259.604.12HorizantPostherpetic Neuralgia6/9/2012Approved
ARIA8.449.894.90RidaforolimusSoft tissue or bone sarcoma6/6/2012CRL
EBS34.0034.4919.31BioThraxAnthrax Vaccine5/17/2012ApprovedApproved May 17 2012
TLON0.161.830.13MarqiboPhiladelphia chromosome-negative acute lymphoblastic leukemia 5/13/2012Extended
ALXA1.165.270.80ADASUVESchizophrenia5/3/2012CRL
PLX1.863.651.53Taliglucerase alfa Gaucher disease5/1/2012Approved
VVUS2.295.132.05AvanafilErectile dysfunction4/29/2012Approved
PGNX8.049.274.26Subcutaneous RELISTORChronic pain4/27/2012ExtendedPrice shown is for PGNX
FURX0.00#N/A#N/AAlogliptinDiabetes - Type 24/25/2012CRL
VVUS2.295.132.05QnexaObesity4/17/2012Extended
CHTPNORTHERA Neurogenic Orthostatic Hypotension3/28/2012CRLAcquired by Lundbeck
AFFY0.090.290.07PeginesatideAnemia in chronic renal failure (CRF)3/27/2012ApprovedBankrupt
MAPPLevadexMigraine3/26/2012CRLAcquired by Allergan
CRIS3.383.651.09VismodegibBasal Cell Carcinoma3/8/2012ApprovedEarly decision Jan 30,2012
NGSX0.010.010.00QutenzaNeuropathic pain associated with HIV-associated peripheral neuropathy (HIV-PN)3/7/2012CRL
DSCO0.632.010.58Surfaxin Respiratory Distress Syndrome - Severe3/6/2012Approved
ASTXDacogenAcute myeloid leukemia3/6/2012CRLAcquired by Otsuka
CBRX#N/A#N/A#N/AProgesterone vaginal gelReduction of risk of preterm birth2/26/2012CRL
CORT5.917.672.27Corlux - KorlymCushing's Syndrome2/17/2012Approved
BPAXBio-T-GelMale hypogonadism2/14/2012ApprovedMerged. New ticker ANIP
ALXA1.165.270.80ADASUVESchizophrenia2/4/2012Extended 3months
AMLNBYDUREONType 2 diabetes1/28/2012ApprovedAcquired by Bristol-Myers Squibb
ALKS67.0575.1738.49BYDUREONType 2 diabetes1/28/2012Approved
PLX1.863.651.53Taliglucerase alfa Gaucher disease1/2/2012Extended 3 monthsInformed Dec 6 2011
NEOLSUBSYSCancer pain1/1/2012ApprovedNew ticker INSY
AIS2.29142.70128.00AnturolOveractive bladder12/8/2011ApprovedChanged ticker to ATRS
INCY117.03117.4243.86JakafiMyelofibrosis12/3/2011ApprovedApproved Nov 16 2011
TSPT#N/A#N/A#N/AIntermezzoInsomnia11/27/2011Approved
SPPI7.278.505.45Removal of the Bioscan Requirement for ZevalinNon-Hodgkin's lymphoma11/20/2011Approved
ALIM4.84ILUVIENDiabetic macular edema11/12/2011CRLEarly CRL. Price shown is for ALIM
IGXT0.580.900.33CPI-300Major Depressive Disorder11/10/2011Approved
PCRX67.77121.9565.00EXPARELPostsurgical pain10/28/2011Approved
SGEN48.9949.8430.05ADCETRISHodgkin lymphoma8/30/2011Approved
SGEN48.9949.8430.05ADCETRISAnaplastic large cell lymphoma8/30/2011Approved
PATHZelrixMigraine8/29/2011CRLAcquired by TEVA.
MSTX0.500.690.40ExelbineNSCLC8/9/2011CRLNew ticker MSTX. Formerly ANX
TSPT#N/A#N/A#N/AIntermezzoInsomnia7/14/2011CRL
PTIE1.775.221.60REMOXYModerate to severe pain6/23/2011CRL
FCSC5.496.402.28LavivWrinkles6/22/2011Approved
ACUR0.901.350.41OxectaPain relief6/17/2011Approved
OPTRFidaxomicinCDI - diarrhea5/30/2011Approved
SPPI7.278.505.45FUSILEVColorectal cancer4/29/2011Approved
XNPT7.259.604.12HorizantRestless Legs Syndrome4/6/2011Approved
HGSI0.00BENLYSTALupus3/10/2011Approved
PLX1.863.651.53Taliglucerase alfa Gaucher disease2/25/2011CRL
OREX4.829.373.11ContraveObesity1/31/2011CRL
DEPO30.8231.189.85GRALISEPostherpetic neuralgia - shingles1/30/2011Approved
MNKD5.5610.183.46AfrezzaInsulin1/26/2011CRLEarly CRL
CLDA#N/AViibrydMajor depressive disorder1/23/2011ApprovedAcquired by Forest Laboratories (FRX)
PSDV/ALIM#N/AILUVIENDiabetic macular edema12/29/2010CRLEarly CRL. Price shown is for ALIM
CADX0.00OFIRMEVPain and fever11/4/2010Approved
BIOD1.112.180.95VIAjectDiabetes10/30/2010CRL
AVNR16.9617.053.02NUEDEXTAPseudobulbar affect10/30/2010Approved
VVUS2.295.132.05QnexaObesity10/28/2010CRL
ALKS/AMLN#N/ABYDUREONType 2 diabetes10/22/2010CRL
ISTA0.00BROMDAYPostoperative inflammation and reduction of ocular pain10/16/2010ApprovedAcquired by Bausch + Lomb
QCOR0.00#N/A#N/AActharInfantile spasms10/15/2010Approved
ALXA1.165.270.80ADASUVESchizophrenia10/11/2010CRL
JAZZ183.23191.01131.69JZP-6Fibromyalgia10/11/2010CRL
HGSIZALBINHepatitis C10/5/2010CRLAcquired by GSK
PGNX8.049.274.26RelistorOpioid-induced constipation (OIC)9/29/2010Approved
SVNTKRYSTEXXAGout9/14/2010ApprovedBankrupt
QCOR0.00#N/A#N/AActharInfantile spasms6/11/2010Extended 4 months
POZN10.7912.695.96VIMOVOGastric ulcers4/30/2010Approved
ITMN0.00#N/A#N/AEsbrietIdiopathic pulmonary fibrosis 4/5/2010CRL
SLXP172.81172.9886.00XIFAXANHepatic encephalopathy3/24/2010Approved
CTIC1.972.941.65PixuvriNon-Hodgkin's lymphoma3/23/2010CRL
SOMX3.005.441.29SilenorInsomnia3/19/2010Approved
APPA32.78APF530Chemotherapy-induced nausea and vomiting3/18/2010CRLChanged ticker to HRTX
SUPG0.00DacogenMyelodysplastic syndromes3/8/2010ApprovedChanged ticker to ASTX
ALKS67.05BYDUREONType 2 diabetes3/5/2010CRLPrice shown is for ALKS
CRXXExalgoModerate to severe pain in opioid tolerant patients3/2/2010ApprovedChanged ticker to ZLCS
CADXOFIRMEVPain and fever2/12/2010CRL
DDSS#N/AOleptroMajor depressive disorder2/11/2010ApprovedBankrupt
XNPT7.259.604.12HorizantRestless Legs Syndrome2/9/2010CRL
PLX1.863.651.53Taliglucerase alfa Gaucher disease2/9/2010Extended
ACOR35.2345.4528.26AMPYRAImprove walking in patients with multiple sclerosis1/22/2010Approved
MNKD5.5610.183.46AFREZZADiabetes1/16/2010CRLFDA responded 15 Mar 2010
FCSC5.496.402.28LavivWrinkles1/4/2010CRLEarly CRL
VIONOnriginAcute myeloid leukemia12/12/2009CRLBankrupt
SOMX3.005.441.29SilenorInsomnia12/4/2009CRL
SNTSZEGERIDGERD12/4/2009ApprovedAcquired by Salix.
DYAX27.9730.558.09KALBITORHereditary angioedema 12/1/2009Approved
NGSX0.010.00QutenzaPostherpetic neuralgia11/16/2009Approved
CADXOFIRMEVMild to moderate pain11/13/2009Approved
TSPT#N/A#N/A#N/AIntermezzoInsomnia11/2/2009CRL
GTXI1.381.590.41ToremifeneReduce fractures in men with prostate cancer10/30/2009CRL
SPPI7.278.505.45FUSILEVColorectal cancer10/8/2009CRL
ALTH#N/A#N/AFOLOTYNPeripheral T-cell lymphoma9/24/2009Approved
ISTABepreveAllergic conjunctivitis9/14/2009ApprovedAcquired by Bausch + Lomb
SPPI7.278.505.45ZEVALINNon-Hodgkin's Lymphoma 9/7/2009Approved
NGSX0.010.010.00QutenzaPostherpetic neuralgia8/17/2009Extended 3 months
SVNTKRYSTEXXAGout8/3/2009CRLBankrupt
DDSS#N/AOleptroMajor depressive disorder7/20/2009CRLBankrupt
ZGNX17.6717.868.56SumavelMigraine7/15/2009Approved
ARDM7.35SumavelMigraine7/15/2009Approved
SPPI7.278.505.45ZEVALINNHL7/2/2009CRL
HEB0.200.400.17AmpligenChronic fatigue syndrome5/25/2009CRLCRL PR released Dec 1, 2009. PDUFA date was May 25, 2009. FDA advised only of a 1-2 week delay

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.

2 Responses to “FDA Historical Calendar”

  1. Chirag says:

    a thousand thanks !!

Leave a Reply